Digital Genome Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 30.68 Billion |
| Market Size (2029) | USD 57.68 Billion |
| CAGR (2024 - 2029) | 13.46 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Digital Genome Market Analysis
The Global Digital Genome Market size is estimated at USD 30.68 billion in 2024, and is expected to reach USD 57.68 billion by 2029, growing at a CAGR of 13.46% during the forecast period (2024-2029).
The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the digital genome market worldwide. The pandemic has positively impacted the demand for digital genome software and products. For instance, as per a February 2022 published article titled, "Covid-19 and Artificial Intelligence: Genome sequencing, drug development, and vaccine discovery", the sequence of SARS- CoV-2 was identified with the help of AI and also aids in the prompt identification of variants of concern (VOC) as delta strains and Omicron. In addition, as per a May 2022 update by the Pan American Health Organization (PAHO), the COVID-19 Genomic Surveillance Regional Network was created in 2020 not only to strengthen the sequencing capacity in the participating laboratories but also for them to establish a routine SARS-CoV-2 genomic sequencing, as a strategy to increase the amount of genetic sequence data available to the global community, which is critical to support the development of diagnostic protocols, the information for vaccine development and to better understand the evolution and molecular epidemiology of the SARS-CoV-2. Moreover, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to increase the demand for digital genome products, thereby contributing to market growth.
The major factors fueling the market growth are the increasing technological advancements pertaining to the digital genome, growing adoption of personalized medicine, constantly evolving disease patterns as well as rising research and development activities about the digital genome.
The increasing technological advancement pertaining to the digital genome is proliferating market growth. For instance, in July 2021, GE Healthcare and SOPHiA GENETICS, a global healthcare data-sharing network, collaborated on advancing cancer care by developing genomic-based AI. The integration of genomics-based artificial intelligence into oncology workflow solutions would be a breakthrough for integrated cancer medicine and for future clinical research, which increasingly depends on the ability to select those patients most likely to respond to new therapies.
In addition, in April 2021, Genome Medical, a digital health company bringing genetics and genomics into everyday care, expanded its technology offering to augment the clinical services provided by its nationwide team of genetics specialists. Genome Medical will automate the collection of a patient's comprehensive family health history and incorporate the findings into an accurate and timely genetic risk assessment rough an exclusive licensing of Health Heritage, a family medical history, and genomic decision support application.
However, high capital expenditure and a lack of a skilled workforce are the factors hindering the market growth.
Digital Genome Market Trends
This section covers the major market trends shaping the Digital Genome Market according to our research experts:
Sequencing and Analysis Software Segment is Expected to Hold a Major Market Share in the Digital Genome Market Over the Forecast Period
By product, sequencing and analysis software segmented is expected to hold a major market share. Sequence analysis is the process of subjecting a DNA, RNA, or peptide sequence to any of a wide range of analytical methods to understand its features, function, structure, or evolution, and methodologies used include sequence alignment and searches against biological databases and others. The major factors fueling the market growth are the increasing research in sequence analysis as well as growing technological advancements.
Several market players are also contributing to the market growth. For instance, in July 2020, Illumina, Inc. introduced turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight Software Suite.
Also, in May 2022, NanoString Technologies, Inc. launched a seamless, cloud-based workflow that improves the spatial data analysis experience of customers using Illumina NextSeq 1000 and NextSeq 2000 sequencing systems and the GeoMx Digital Spatial Profiler.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall genomics market throughout the forecast period due to the rising incidence of chronic diseases, such as cancer, increasing government entities' investment in research, raising awareness of patients, and the availability of advanced healthcare infrastructure, contributing to the growing technological advances in this sector and rising demand for biotechnological practices in the region, is anticipated to drive the growth in the region. The domicile presence of some of the major players in the region also ensures the dominance of the region.
The current global pandemic created considerable opportunities for the domestic market players operating in the space. For instance, in March 2021, Applied DNA Sciences Inc. launched the Linea COVID-19 Selective Genomic Surveillance Mutation Panel to enhance the utility of limited Next Generation Sequencing (NGS) resources in the United States to track the SARS-CoV-2 Variants of Concern (VOCs) better at local, state, and federal levels.
In April 2021, Inscripta, a digital genome engineering company, announced the first commercial shipment of its Onyx platform. The platform is the world's first fully automated benchtop instrument for genome-scale engineering. Inscripta also announced its Series E funding of USD 150 million.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
Digital Genome Industry Overview
The digital genome market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are bioMérieux, Agilent Technologies, Inscripta, Inc., GE Healthcare, and Invitae Corporation.
Digital Genome Market Leaders
-
bioMérieux
-
Agilent Technologies
-
Inscripta, Inc.
-
GE Healthcare
-
Invitae Corporation
*Disclaimer: Major Players sorted in no particular order
Digital Genome Market News
- In May 2022, Gencove, one of the leading low-pass whole genome sequencing and analysis software companies, along with NEOGEN Corporation, launched the InfiniSEEK, a revolutionary, cost-effective solution for whole genome sequencing and targeted SNP analysis from two trusted leaders in genomics.
- In March 2022, LetsGetChecked, a leading healthcare solutions company, acquired Veritas Genetics Inc. and Veritas Intercontinental, pioneers in genomics that share a scalable platform enabling the rapid interpretation of genetic information from a single gene to the whole genome. The strategic move signifies a crucial advancement in LetsGetChecked's mission to empower individuals to take control of their health and enable both consumers and healthcare partners to be more proactive in healthcare management.
Digital Genome Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Technological Advancements, and Research and Development Pertaining to Digital Genome
- 4.2.2 Growing Adoption of Personalized Medicine
- 4.2.3 Constantly Evolving Disease Patterns
-
4.3 Market Restraints
- 4.3.1 High Capital Expenditure
- 4.3.2 Lack of Skilled Workforce
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Sequencing and Analyzer Instruments
- 5.1.2 DNA/RNA Analysis Kits
- 5.1.3 Sequencing Chips
- 5.1.4 Sequencing and Analysis Software
- 5.1.5 Sample Preparation Instruments
-
5.2 By Application
- 5.2.1 Clinical
- 5.2.1.1 Reproductive Health
- 5.2.1.2 Oncology
- 5.2.1.3 Others
- 5.2.2 Forensics
- 5.2.3 Drug Discovery and Development
- 5.2.4 Other Applications
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Diagnostic Centers and Forensic Labs
- 5.3.3 Research Institutes
- 5.3.4 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Agilent Technologies
- 6.1.2 Inscripta, Inc.
- 6.1.3 bioMérieux
- 6.1.4 GE Healthcare
- 6.1.5 Invitae Corporation
- 6.1.6 GenMark Diagnostics, Inc.
- 6.1.7 Illumina
- 6.1.8 NanoString Technologies, Inc.
- 6.1.9 Pacific Bioscience
- 6.1.10 PerkinElmer Inc.
- 6.1.11 Quest Diagnostics
- 6.1.12 Qiagen
- 6.1.13 Thermo Fisher Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDigital Genome Industry Segmentation
As per the scope of the report, the digital genome is a comprehensive digital set of genetic material that occurs in a cell or an organism to gather information concerning chronic diseases and is utilized by experts to get a nearer look at genetic disorders. The market is segmented by product (Sequencing and Analyzer Instruments, DNA/RNA Analysis kits, Sequencing Chips, Sequencing and Analysis Software, Sample Preparation Instruments, and Other Products), Application (Clinical (Reproductive health, oncology, and others), Forensics, Drug discovery and development, and other applications), End-user (Hospitals, Diagnostic centers, and Forensic labs, Research Institutes, Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | Sequencing and Analyzer Instruments | |
| DNA/RNA Analysis Kits | ||
| Sequencing Chips | ||
| Sequencing and Analysis Software | ||
| Sample Preparation Instruments | ||
| By Application | Clinical | Reproductive Health |
| Oncology | ||
| Others | ||
| By Application | Forensics | |
| Drug Discovery and Development | ||
| Other Applications | ||
| By End User | Hospitals | |
| Diagnostic Centers and Forensic Labs | ||
| Research Institutes | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Digital Genome Market Research FAQs
How big is the Global Digital Genome Market?
The Global Digital Genome Market size is expected to reach USD 30.68 billion in 2024 and grow at a CAGR of 13.46% to reach USD 57.68 billion by 2029.
What is the current Global Digital Genome Market size?
In 2024, the Global Digital Genome Market size is expected to reach USD 30.68 billion.
Who are the key players in Global Digital Genome Market?
bioMérieux , Agilent Technologies, Inscripta, Inc., GE Healthcare and Invitae Corporation are the major companies operating in the Global Digital Genome Market.
Which is the fastest growing region in Global Digital Genome Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Digital Genome Market?
In 2024, the North America accounts for the largest market share in Global Digital Genome Market.
What years does this Global Digital Genome Market cover, and what was the market size in 2023?
In 2023, the Global Digital Genome Market size was estimated at USD 27.04 billion. The report covers the Global Digital Genome Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Digital Genome Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Digital Genome Industry Report
Statistics for the 2023 Digital Genome market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Digital Genome analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
